Manufacturing Issues Stoke Fears of EpiPen Shortage in Britain

Back to QNT News

FiercePharma Manufacturing

April 11, 2018

By Joseph Keenan

Manufacturing problems have created a shortage of Mylan’s EpiPens in Britain, forcing the company to ration the devices allergy patients rely on to treat anaphylactic shock.

The company announced it will ration the devices, which contain doses of adrenaline, the Daily Mail reported. A spokesperson for the company told the newspaper the shortage is the result of manufacturing delays at a subsidiary firm owned by Pfizer. Mylan has previously warned of global supply issues with the device.

The spokesperson, who was not named, told the Daily Mail the company is currently unable to determine “when the supply constraint will be fully resolved.”

An unnamed Pfizer spokesperson said, “We understand how important this potentially life-saving product is to patients,” adding that it is “working tirelessly to increase production and expedite shipments as rapidly as possible.”

The shortage could affect tens of thousands of patients in the country.

EpiPen competitors Bausch+Lomb, maker of Emerade, along with Denmark’s ALKAbelló, maker of Jext, are rushing to make up the shortfall of the treatment, the newspaper said.

Last summer, Mylan came under intense criticism for its repeated price hikes on EpiPen, which had taken the lifesaving injector’s list price up several hundred percent over previous years. As a result of the controversy, Mylan beefed up its patient access program and rolled out a cheaper authorized generic.

Copyright 2018 Questex Media Group LLC. All Rights Reserved.

Copyright © LexisNexis, a division of Reed Elsevier Inc. All rights reserved.  
Terms and Conditions    Privacy Policy

Quality News Today is an ASQ member benefit offering quality related news
from around the world every business day.

ASQ is a global community of people passionate about quality, who use the tools, their ideas and expertise to make our world work better. ASQ: The Global Voice of Quality.